FGEN and ALPMY Related Headlines
Go Back- Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
- FibroGen (FGEN) to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week
- FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
- European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat
- European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat
FGEN and ALPMY Related Press Releases
Go Back- Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
- FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
- European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat
- European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat